With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new ...

STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers ...